United States - English - NLM (National Library of Medicine)

endo pharmaceuticals inc. - histrelin acetate (unii: qmg7hld1ze) (histrelin - unii:h50h3s3w74) - histrelin acetate 50 mg - supprelin la (histrelin acetate) subcutaneous implant is indicated for the treatment of children with central precocious puberty (cpp). children with cpp (neurogenic or idiopathic) have an early onset of secondary sexual characteristics (earlier than 8 years of age in females and 9 years of age in males). they also show a significantly advanced bone age that can result in diminished adult height attainment. prior to initiation of treatment a clinical diagnosis of cpp should be confirmed by measurement of blood concentrations of total sex steroids, luteinizing hormone (lh) and follicle stimulating hormone (fsh) following stimulation with a gnrh analog, and assessment of bone age versus chronological age. baseline evaluations should include height and weight measurements, diagnostic imaging of the brain (to rule out intracranial tumor), pelvic/testicular/adrenal ultrasound (to rule out steroid secreting tumors), human chorionic gonadotropin levels (to rule out a chorionic gonadotropin secreting tumor), and adre

United States - English - NLM (National Library of Medicine)

endo pharmaceuticals inc. - histrelin acetate (unii: qmg7hld1ze) (histrelin - unii:h50h3s3w74) - histrelin acetate 50 mg - vantas is indicated for the palliative treatment of advanced prostate cancer. vantas is contraindicated in patients who are hypersensitive to gonadotropin releasing hormone (gnrh) or gnrh agonist analogs. risk summary the safety and efficacy of vantas have not been established in females. based on findings in animal studies and its mechanism of action, vantas can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . expected hormonal changes that occur with vantas treatment increase the risk for pregnancy loss. the limited data with histrelin use in pregnant women are insufficient to determine a drug-associated risk for major birth defects or adverse developmental outcomes. in animal reproduction studies, administration of histrelin to pregnant rats and rabbits during the period of organogenesis caused an increase in fetal loss at clinically relevant exposures (see data) . advise pregnant patients and females of reproductive potential of the potential risk to the fetus. d

United States - English - NLM (National Library of Medicine)

attix pharmaceuticals - histrelin acetate (unii: qmg7hld1ze) (histrelin - unii:h50h3s3w74) -

United States - English - NLM (National Library of Medicine)

zhejiang peptites biotech co., ltd - histrelin acetate (unii: qmg7hld1ze) (histrelin - unii:h50h3s3w74) -

United States - English - NLM (National Library of Medicine)

ax pharmaceutical corp - histrelin acetate (unii: qmg7hld1ze) (histrelin acetate - unii:qmg7hld1ze) - histrelin acetate .99 g in 1 g

Ireland - English - HPRA (Health Products Regulatory Authority)

orion corporation - histrelin acetate - implant - 50 milligram

Canada - English - Health Canada

paladin labs inc. - histrelin acetate - implant - 50mg - histrelin acetate 50mg - antineoplastic agents

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

orion pharma (uk) ltd - histrelin acetate - prolonged-release subcutaneous implant - 50mg

Ireland - English - HPRA (Health Products Regulatory Authority)

orion corporation - histrelin acetate - implant - 50 milligram

Canada - English - Health Canada

verity pharmaceuticals inc. - leuprolide acetate - powder for suspension, sustained-release - 3.75mg - leuprolide acetate 3.75mg - antineoplastic agents